Roberto Barriales-Villa

Nov 13, 2024 | nature.com | William Young |Nay Aung |Luis Lopes |Perry Elliott |Petros Syrris |Roberto Barriales-Villa | +3 more

AbstractHeart shape captures variation in cardiac structure beyond traditional phenotypes of mass and volume. Although observational studies have demonstrated associations with cardiometabolic risk factors and diseases, its genetic basis is less understood. We utilised cardiovascular magnetic resonance images from 45,683 UK Biobank participants to construct a heart shape atlas from bi-ventricular end-diastolic surface mesh models through principal component (PC) analysis.

Sep 4, 2024 | jamanetwork.com | Ahmad Masri |Michael E. Nassif |Kansas City |Roberto Barriales-Villa

Key PointsQuestion  Does aficamten treatment improve exercise response beyond peak oxygen uptake (pVO2) measured by cardiopulmonary exercise testing in obstructive hypertrophic cardiomyopathy (HCM)? Findings  In the Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) randomized clinical trial, 282 patients with symptomatic obstructive HCM received aficamten or placebo for 24 weeks.

Feb 2, 2024 | onlinelibrary.wiley.com | Ahmad Masri |Roberto Barriales-Villa |Perry M. Elliott

Introduction Non-obstructive hypertrophic cardiomyopathy (nHCM) is a growing segment of the population with hypertrophic cardiomyopathy (HCM); however, no evidence-based medical therapies have been shown to improve symptoms, quality of life, or exercise capacity.1 Aficamten is a next-in-class cardiac myosin inhibitor that targets hypercontractility and impaired myocardial relaxation.2 Aficamten appears to be safe and effective in patients with obstructive HCM (oHCM) studied in the phase 2...